|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, the results of this study suggest that the expression of miR-126-3p in the tumour tissue was associated with outcome of metastatic colorectal cancer patients treated with bevacizumab.
|
28714375 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, microRNA-126 levels were high in 6 epithelial tumours (mammary, hepatocellular, squamous cell, thyroid, transitional cell carcinomas, and adenocarcinoma) and 4 non-epithelial tumours (osteosarcoma, mast cell tumour, melanoma, and hemangiosarcoma).
|
28536479 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our results suggest that miR-126 is a tumor suppressor by sensitizing GC cells to chemotherapy and provide a potential therapeutic approach in cancer treatment.
|
27622325 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vivo study showed that tumor growth was significantly suppressed by miR-126 overexpression.
|
28536606 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrated the responsibility of the circuitry connecting the oncomiR-221&222 with the tumor suppressors miR-126&126* in melanoma development and progression.
|
26434590 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, these results demonstrated that miR-126 acts as a tumor suppressor by inactivating RhoA signaling via CXCR4 in colon cancer.
|
27517626 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor xenograft model in nude mice was utilized to evaluate the influence of miR-126 on tumor growth.
|
27611944 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistently, MIR126-expressing MM cells injected into immunocompromised mice failed to progress beyond the initial stage of tumor formation, showing that increased autophagy has a protective role in MM.
|
27119351 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, our data demonstrated that miR-126-3p is a tumor suppressor miRNA that acts by targeting PIK3R2 in Kaposi's sarcoma cells.
|
27191494 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The modulatory role of miR-126 on expression of VEGF-A and its tumor suppressive roles were demonstrated for the first time in thyroid cancer.
|
27067785 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
microRNA-126 (miR-126) has been reported to play tumor suppressor roles in various types of cancers.
|
26239517 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
"Exosomal onco-miRs" such as miR-223-5p, miR-223-3p, miR-483-5p, miR-409-3p, miR-196b-5p, miR-192-5p, miR-146a-5p, and miR-126-5p have been identified as part of exosomal cargo being overexpressed in corresponding tumor compared to normal.
|
25631748 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Down regulation of miR-126 expression was associated with histological subtypes, peri-neural tumour infiltration, microsatellite instability and pathological staging of colorectal cancers (p<0.05).
|
26455548 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In term of miR-126, our results showed that miR-126 was associated with tumor stage and lymph nodes metastasis (P<0.05).
|
26823832 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these findings showed that miR-126 functions as a tumor suppressor in glioma cells by targeting IRS-1 expression via the PI3K/AKT signaling pathways, suggesting that miR-126 might be a novel target for therapeutic strategies in glioma.
|
26617742 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our study suggests that miR-126 functions as a potential tumor suppressor in ESCC progression via regulating PI3K/AKT signaling pathway partly by targeting PIK3R2, and targeting of miR-126 may provide a novel strategy for the diagnosis and treatment of ESCC.
|
26191164 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our study revealed that miR-126 may act as a tumor suppressor via inhibition of cell invasion by downregulating ADAM9 in breast cancer development.
|
26261534 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that low miR-126 expression had significant association with advanced TNM stage (P <0.001), distant metastasis (P <0.001), and higher tumor grade (P = 0.001).
|
26194657 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, to explore the mechanism of miR-126-mediated tumor suppression, we searched the putative targets of miR-126 using prediction program.
|
25585946 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We analyzed the expressions of miR-126 and miR-20b in 136 colorectal tumors from 39 microsatellite stable (MSS) tumors, 23 high microsatellite instability (MSI-H) tumors, 16 Lynch syndrome, and 58 familial adenomatous polyposis (FAP) tumors including adenoma, intramucosal carcinoma, and invasive carcinoma.
|
24994098 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, the present study demonstrated that miR-126 acts as a tumor suppressor in OSCC cells, partially at least via the downregulation of EGFL7.
|
24789258 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR126 affects mitochondrial energy metabolism, resulting in MM tumor suppression.
|
24444362 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-126 was reported to act as a tumor suppressor by targeting the Crk gene, or as an oncogene by targeting the SOX2 gene in gastric cancer.
|
24969300 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among the microRNAs (miRNAs) that control different cellular processes, miR-24, miR-126 and miR-365 were shown to regulate cell cycle progression and apoptosis in various types of tumors.
|
24153013 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, the results from our study suggested that miR-126 could suppress tumor growth and tumor angiogenesis of GC through VEGF-A signaling, and it is a novel potential therapeutic target for GC.
|
25428912 |
2014 |